Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.50 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.46 |
| ▸ | PDE4A | P27815 | 1/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | TOP1 | P11387 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5706423 | 1.00 | LMNA (0.52) | LMNAL3MBTL1TDP1USP2SLCO1B1 | |
| SCHEMBL8586304 | 1.00 | LMNA (0.52) | LMNAL3MBTL1TDP1USP2SLCO1B1 | |
| SCHEMBL420278 | 1.00 | LMNA (0.52) | LMNAL3MBTL1TDP1USP2SLCO1B1 | |
| SCHEMBL17493340 | 1.00 | LMNA (0.52) | LMNAL3MBTL1TDP1USP2SLCO1B1 | |
| SCHEMBL2066243 | 1.00 | LMNA (0.52) | LMNAL3MBTL1TDP1USP2SLCO1B1 | |
| SCHEMBL1548302 | 1.00 | LMNA (0.52) | LMNAL3MBTL1TDP1USP2SLCO1B1 | |
| SCHEMBL2227363 | 1.00 | LMNA (0.52) | LMNAL3MBTL1TDP1USP2SLCO1B1 | |
| SCHEMBL3116850 | 1.00 | LMNA (0.52) | LMNAL3MBTL1TDP1USP2SLCO1B1 | |
| SCHEMBL22963142 | 1.00 | LMNA (0.52) | LMNAL3MBTL1TDP1USP2SLCO1B1 | |
| SCHEMBL28730 | 1.00 | LMNA (0.52) | LMNAL3MBTL1TDP1USP2SLCO1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2149581-A1 | MONOMER AND COMPOSITION FOR PRODUCING LOW-PERCENTAGE HYDROGEL AND/OR HYDROGEL HAVING A LOW CROSS LINKAGE CONTENT, A HYDROGEL AND A BIOCHIP BASED THEREON | Institut Molekulyarnoi Biologii Im. V.A. Engelgardta Rossiiskoi Akademii Nauk (RU) | 2010-02-03 | — | — | EP | claimed |
| US-20040029815-A1 | Compositions and methods for treating cancer | THRESHOLD PHARMACEUTICALS, INC. | 2004-02-12 | — | — | US | claimed |
| WO-2003082301-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THRESHOLD PHARMACEUTICALS, INC. (US) | 2003-10-09 | — | — | WO | claimed |
| US-11421223-B2 | Processes and host cells for genome, pathway, and biomolecular engineering | ENEVOLV, INC. (US) | 2022-08-23 | — | — | US | disclosed |
| CN-113906144-A | Optimal chromosomal insertion loci | 因比奥斯公司 | 2022-01-07 | — | — | CN | disclosed |
| US-20190309289-A1 | PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING | ENEVOLV, INC. | 2019-10-10 | — | — | US | disclosed |
| US-10370654-B2 | Processes and host cells for genome, pathway, and biomolecular engineering | ENEVOLV, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-20180320170-A1 | PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING | ENEVOLV, INC. | 2018-11-08 | — | — | US | disclosed |
| US-9944925-B2 | Processes and host cells for genome, pathway, and biomolecular engineering | ENEVOLV, INC. | 2018-04-17 | — | — | US | disclosed |
| US-20160186168-A1 | PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING | ENEVOLV, INC. | 2016-06-30 | — | — | US | disclosed |
| US-9045514-B2 | Methods for producing amino-substituted glycolipid compounds | DUPONT NUTRITION BIOSCIENCES APS (DK) | 2015-06-02 | — | — | US | disclosed |
| EP-0829104-A1 | HIGH ENERGY DENSITY VANADIUM ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND ALL-VANADIUM REDOX CELLS AND BATTERIES CONTAINING HIGH ENERGY VANADIUM ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1998-03-18 | — | — | EP | disclosed |
| US-5631389-A | SUCCINAMIDES WITH SUGAR GROUPS, POLLUTION CONTROL, BIODEGRADABLE | LEVER BROTHERS COMPANY, DIVISION OF CONOPCO, INC. (US) | 1997-05-20 | — | — | US | disclosed |
| EP-0729648-A4 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LTD (AU) | 1997-01-02 | — | — | EP | disclosed |
| WO-1996035239-A1 | HIGH ENERGY DENSITY VANADIUM ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND ALL-VANADIUM REDOX CELLS AND BATTERIES CONTAINING HIGH ENERGY VANADIUM ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1996-11-07 | — | — | WO | disclosed |
| EP-0729648-A1 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1996-09-04 | — | — | EP | disclosed |
| US-5541341-A | CARBOHYDRATE BASED SURFACTANTS | LEVER BROTHERS COMPANY, DIVISION OF CONOPCO, INC. (US) | 1996-07-30 | — | — | US | disclosed |
| WO-1995012219-A1 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1995-05-04 | — | — | WO | disclosed |
| EP-0059911-A1 | Cis-platinous(II) complexes with saccharide derivatives as ligands | BASF Aktiengesellschaft (DE) | 1982-09-15 | — | — | EP | disclosed |
| US-4224440-A | NON-IONIC X-RAY CONTRAST AGENTS | MALLINCKRODT, INC. (US) | 1980-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029815-A1 | Compositions and methods for treating cancer | SLC2A2, SLC2A1, SLC2A3 | LMNA 1299/4885L3MBTL1 2810/4885TDP1 2319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.